When was Sarepta founded?

Sarepta was founded in 1980 and raised its 1st funding round 26 years after it was founded.

Where is Sarepta located?

Sarepta is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Sarepta have?

As of Oct 31, 2026, the latest employee count at Sarepta is 1175.

Is Sarepta a funded company?

Sarepta is a funded company, having raised an undisclosed amount across 7 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Dec 01, 2006.

When was the latest funding round of Sarepta?

Sarepta's latest funding was a $***** Post IPO round on Feb 28, 2020, with participation from 0 investor.

What is the annual revenue of Sarepta?

Annual revenue of Sarepta is more than $1B as on Dec 31, 2025

Where does Sarepta rank among its competitors?

Sarepta ranks 135th amongst 863 active competitors, of which 293 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Aspen Neuroscience, which secured $115M in Nov, 2025.

Who are the top competitors of Sarepta?

Sarepta's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, Aspen Neuroscience secured the most recent funding round in November, 2025.

Sarepta - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of RNA-targeted therapeutics for the treatment of rare and infectious diseases. The company engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. It has a proprietary antisense Phosphorodiamidate Morpholino Oligomers platform to design targeted therapies. The company develops pipeline of products for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and more.

Website: www.sarepta.com/
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

1980

Location

Cambridge, United States

Stage

Public

Latest Funding Round

Post IPO, Feb 28, 2020, $*****

Investors

Avoro Capital & 13 more

Ranked

135^th among 863 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

1,175 as on Oct 31, 2026

Investment & Acquisitions

LEXEO Therapeutics & 5 more

Similar Companies

BridgeBio & 1039 more

Exit Details

Public

View Sarepta's full profile

Sarepta is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Sarepta Therapeutics, Inc. CIN: 873303 , United States, Active		$1B+ (As on Dec 31, 2025)	-	-
Sarepta Therapeutics, Inc. CIN: 930797222 , United States, Active	Dec 26, 999	-	1354 (As on Dec 31, 2024)	-

Sarepta got listed on Jun 03, 1997.

Click here to take a look at Sarepta's IPO in detail

Sarepta has raised funding over 7 rounds. Its first funding round was on Dec 01, 2006. Sarepta has 14 institutional investors.

Here is the list of recent funding rounds of Sarepta:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 28, 2020	6079112	Post IPO	5383714	8822302	2501540	2183094
Nov 25, 2019	6800488	Post IPO	1451655	2005336	6047393	4177978
Oct 06, 2015	2246267	Post IPO	8646032	7916244	2811990	Morgan Stanley & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Sarepta's funding rounds and investors

Sarepta's employee count trend

Sarepta has 1,175 employees as of Oct 26. Here is Sarepta's employee count trend over the years:

Uncover Sarepta's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sarepta include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Sarepta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 22 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 14 others	81/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 29 others	73/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	72/100
5th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	72/100
6th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	72/100
7th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
8th	Aspen Neuroscience 2018, San Diego (United States), Public	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Revelation Partners, Orbimed & 22 others	69/100
9th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	69/100
10th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	69/100
135th	Sarepta 1980, Cambridge (United States), Public	Developer of RNA-targeted therapeutics for the treatment of rare and infectious diseases	-	Avoro Capital, Vulcan Capital & 12 others	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Sarepta's competitors? Click here to see the top ones

Sarepta has made 5 investments in companies including LEXEO Therapeutics and StrideBio. Sarepta has also acquired 1 companies including Myonexus Therapeutics.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Aug 28, 2023	Investments	LEXEO Therapeutics	2018	New York City (United States)
Mar 16, 2021	Investments	StrideBio	2015	Durham (United States)
Oct 22, 2020	Investments	AAVANTIBio	2017	Gainesville (United States)